Hydrogen-Rich Saline as an Innovative Therapy for Cataract: A Hypothesis.
Cataract is the leading cause of irreversible blindness worldwide. Increasing evidence indicates that oxidative stress is an important risk factor contributing to the development of cataract. Moreover, the enhancement of the antioxidant defense system may be beneficial to prevent or delay the cataractogenesis. The term oxidative stress has been defined as a disturbance in the equilibrium status of oxidant/antioxidant systems with progressive accumulation of reactive oxygen species (ROS) in intact cells. Superfluous ROS can damage proteins, lipids, polysaccharides, and nucleic acids within ocular tissues that are closely correlated with cataract formation. Therefore, prevention of oxidative stress damage by antioxidants might be considered as a viable means of medically offsetting the progression of this vision-impairing disease. Molecular hydrogen has recently been verified to have protective and therapeutic value as an antioxidant through its ability to selectively reduce cytotoxic ROS such as hydroxyl radical (OH). Hitherto, hydrogen has been used as a therapeutic element against multiple pathologies in both animal models and human patients. Unlike most well-known antioxidants, which are unable to successfully target organelles, hydrogen has advantageous distribution characteristics enabling it to penetrate biomembranes and diffuse into the cytosol, mitochondria, and nucleus. Consequently, we speculate that hydrogen might be an effective antioxidant to protect against lens damage, and it is important to further explore the biological mechanism underlying its potential therapeutic effects.
Department of Ophthalmology, General Hospital of Chinese PLA, Ophthalmology and Visual Science Key Lab of PLA, Beijing, China (mainland).
Limin
L
Qin
Department of Ophthalmology, General Hospital of Chinese PLA, Ophthalmology and Visual Science Key Lab of PLA, Beijing, China (mainland).
Ye
Y
Tao
Department of Ophthalmology, General Hospital of Chinese PLA, Ophthalmology and Visual Science Key Lab of PLA, Beijing, China (mainland).
Liqiang
L
Wang
Department of Ophthalmology, General Hospital of Chinese PLA, Ophthalmology and Visual Science Key Lab of PLA, Beijing, China (mainland).
Hong
H
Chen
Department of Ophthalmology, General Hospital of Chinese PLA, Ophthalmology and Visual Science Key Lab of PLA, Beijing, China (mainland).
Ying
Y
Liu
Department of Ophthalmology, General Hospital of Chinese PLA, Ophthalmology and Visual Science Key Lab of PLA, Beijing, China (mainland).
Yi Fei
YF
Huang
D000818:Animals; D002386:Cataract / Q000188:drug therapy*; D005240:Feasibility Studies; D006801:Humans; D006859:Hydrogen / Q000627:therapeutic use*; D008954:Models, Biological; D012965:Sodium Chloride / Q000627:therapeutic use*; D035703:Therapies, Investigational
D012965:Sodium Chloride; D006859:Hydrogen